Core Viewpoint - Hendi Pharmaceutical (301211.SZ) expects a significant decline in net profit for 2025, projecting a range of 31 million to 39 million yuan, which represents a decrease of 66.14% to 57.40% compared to the previous year [1] Financial Performance - The net profit attributable to shareholders is forecasted to be between 31 million and 39 million yuan, indicating a substantial decline from the previous year [1] - The net profit after excluding non-recurring gains and losses is expected to be between 5.5 million and 8.2 million yuan, reflecting a decrease of 92.46% to 88.76% year-on-year [1] Market Conditions - The decline in profit is attributed to intensified market competition for the main product, ibuprofen raw materials, and certain specialty raw material products, leading to a decrease in gross margin [1] - Additionally, the reduction in interest income from cash management due to falling interest rates has also impacted profitability [1]
亨迪药业(301211.SZ)：预计2025年净利润同比下降57.4%-66.14%